The Potential Predictive Role of Tumour Necrosis Factor-α, Interleukin-1β, and Monocyte Chemoattractant Protein-1 for COVID-19 Patients Survival.
COVID-19
SARS COV-2
cytokine
survival predictors
Journal
Infection and drug resistance
ISSN: 1178-6973
Titre abrégé: Infect Drug Resist
Pays: New Zealand
ID NLM: 101550216
Informations de publication
Date de publication:
2022
2022
Historique:
received:
08
11
2021
accepted:
21
02
2022
entrez:
14
3
2022
pubmed:
15
3
2022
medline:
15
3
2022
Statut:
epublish
Résumé
Tumour necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and monocyte chemoattractant protein-1 (MCP-1) are early phase cytokines often encountered when the body is exposed to severe acute respiratory syndrome-associated-coronavirus-2. TNF-α, IL-1β, and MCP-1 are pro-inflammatory cytokines critical in the defence response against systemic infection and injury. Therefore, TNF-α, IL-1β, and MCP-1 are the most aggressive responses to viral infections in the acute phase, so they can be used to determine the survival of coronavirus disease 2019 (COVID-19) patients. The study aimed to determine the levels of TNF-α, IL-1β, and MCP-1 as predictors of survival for COVID-19 patients. A prospective cohort study was conducted on confirmed COVID-19 by a reverse-transcriptase-polymerase-chain-reaction (RT-PCR) in 84 adults admitted to the hospital in Indonesia. TNF-α, IL-1β, and MCP-1 level were measured from serum subjects using the enzyme-linked immunosorbent assay. The results from logistic regression modelling of the survival status of COVID-19 patients based on TNF-α, IL-1β, and MCP-1 levels were significant (p-value=0.024). The predictors of all cytokines had P Wald <0.05, so the three cytokines could be used simultaneously to predict the survival status of COVID-19 patients. MCP-1 has the most dominant risk relative value (2.76; 95% CI; 2.53-4.68) compared to TNF-α and IL-1β in predicting patient survival. TNF-α, IL-1β, and MCP-1 as markers of acute systemic inflammatory cytokines can be measured at the beginning of hospitalisation of COVID-19 patients for early diagnosis of disease severity so that healthcare professionals can determine clinical guidance needs for therapeutic programs.
Sections du résumé
Background
UNASSIGNED
Tumour necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and monocyte chemoattractant protein-1 (MCP-1) are early phase cytokines often encountered when the body is exposed to severe acute respiratory syndrome-associated-coronavirus-2. TNF-α, IL-1β, and MCP-1 are pro-inflammatory cytokines critical in the defence response against systemic infection and injury. Therefore, TNF-α, IL-1β, and MCP-1 are the most aggressive responses to viral infections in the acute phase, so they can be used to determine the survival of coronavirus disease 2019 (COVID-19) patients.
Purpose
UNASSIGNED
The study aimed to determine the levels of TNF-α, IL-1β, and MCP-1 as predictors of survival for COVID-19 patients.
Patients and Methods
UNASSIGNED
A prospective cohort study was conducted on confirmed COVID-19 by a reverse-transcriptase-polymerase-chain-reaction (RT-PCR) in 84 adults admitted to the hospital in Indonesia. TNF-α, IL-1β, and MCP-1 level were measured from serum subjects using the enzyme-linked immunosorbent assay.
Results
UNASSIGNED
The results from logistic regression modelling of the survival status of COVID-19 patients based on TNF-α, IL-1β, and MCP-1 levels were significant (p-value=0.024). The predictors of all cytokines had P Wald <0.05, so the three cytokines could be used simultaneously to predict the survival status of COVID-19 patients. MCP-1 has the most dominant risk relative value (2.76; 95% CI; 2.53-4.68) compared to TNF-α and IL-1β in predicting patient survival.
Conclusion
UNASSIGNED
TNF-α, IL-1β, and MCP-1 as markers of acute systemic inflammatory cytokines can be measured at the beginning of hospitalisation of COVID-19 patients for early diagnosis of disease severity so that healthcare professionals can determine clinical guidance needs for therapeutic programs.
Identifiants
pubmed: 35281571
doi: 10.2147/IDR.S348392
pii: 348392
pmc: PMC8904436
doi:
Types de publication
Journal Article
Langues
eng
Pagination
821-829Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2022 Kumboyono et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Emerg Microbes Infect. 2020 Dec;9(1):727-732
pubmed: 32196410
Clin Chim Acta. 2020 Oct;509:280-287
pubmed: 32531256
Postgrad Med J. 2020 Jul;96(1137):403-407
pubmed: 32522846
Front Immunol. 2020 Jun 16;11:1446
pubmed: 32612617
J Med Virol. 2020 Oct;92(10):2188-2192
pubmed: 32436996
Front Immunol. 2020 Jul 10;11:1708
pubmed: 32754163
Med Hypotheses. 2020 Nov;144:109935
pubmed: 32795834
JCI Insight. 2021 Jan 11;6(1):
pubmed: 33232303
Mol Med. 2020 Oct 29;26(1):97
pubmed: 33121429
Nature. 2020 Apr;580(7803):E7
pubmed: 32296181
J Med Virol. 2020 Nov;92(11):2600-2606
pubmed: 32470153
Cytokine. 2021 Feb;138:155389
pubmed: 33348065
Microsc Res Tech. 2000 Aug 1;50(3):184-95
pubmed: 10891884
Int J Mol Sci. 2019 Nov 28;20(23):
pubmed: 31795299
Immunol Res. 2020 Jun;68(3):161-168
pubmed: 32524333
Lancet Rheumatol. 2020 Jul;2(7):e428-e436
pubmed: 32835246
Cytokine Growth Factor Rev. 2020 Jun;53:66-70
pubmed: 32418715
N Engl J Med. 2020 Dec 3;383(23):2255-2273
pubmed: 33264547
Microb Pathog. 2021 Apr;153:104799
pubmed: 33609650
J Infect. 2020 Jun;80(6):607-613
pubmed: 32283152
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Front Immunol. 2020 Sep 24;11:558898
pubmed: 33072097
J Interferon Cytokine Res. 2009 Jun;29(6):313-26
pubmed: 19441883
Lancet Respir Med. 2020 Jun;8(6):e46-e47
pubmed: 32353251
Theranostics. 2021 Jan 1;11(1):316-329
pubmed: 33391477
Cell Host Microbe. 2020 Jun 10;27(6):992-1000.e3
pubmed: 32320677
J Clin Med. 2021 Sep 14;10(18):
pubmed: 34575258
Am J Respir Crit Care Med. 2020 Sep 15;202(6):812-821
pubmed: 32584597
Cytokine Growth Factor Rev. 2020 Aug;54:62-75
pubmed: 32513566
Nat Med. 2020 Oct;26(10):1636-1643
pubmed: 32839624
Thromb Res. 2020 Oct;194:101-115
pubmed: 32788101